QuestCap Provides COVID-19 Testing Kits to Kinross Gold’s Russian Operations
January 05 2021 - 7:30AM
QuestCap Inc. (“QuestCap”) (NEO:QSC;
OTC:COPRF; FRA:34C1) is pleased to announce the
completion of an agreement to supply state-of-the-art COVID-19
testing equipment and custom protocols to JSC Chukotka Mining and
Geological Company (“CMGC”), a subsidiary of Kinross Gold (NYSE:
KGC; TSX: K). The equipment supplied included COVID-19 RT-PCR tests
and antibody tests and analyzers that are expected to help test
employees at Kinross’ Kupol and Dvoinoye mines in the Chukotka
region, its Udinsk project in the Khabarovsk region and at its
Russian offices in Magadan and Moscow. The total contract value for
the tests and associated protocols is US$2.1 million.
“We are very excited to be able to partner with
a global mining company like Kinross Gold and help them continue
operating in a COVID-19 environment,” commented Doug Sommerville,
QuestCap CEO. “We know the importance of safety in the mining
industry and are proud to help extend that culture of safety with
state of the art protocols and QuestCap’s high-quality testing
solutions. We look forward to extending this to other businesses
that require our complete COVID-19 testing solution.”
Specifically, QuestCap supplied CMGC with 15
portable RT PCR analyzers, 57,000 RT-PCR tests, and 10,000 Novel
Coronavirus (2019-nCoV) IgM/IgG Rapid Antibody tests.
Equipment training has been conducted with CMGC employees in Russia
with the testing protocols now being implemented. The testing
protocols are expected to test workers for COVID-19 throughout
their work rotations to help prevent the spread of the virus at the
mine and project sites.
“The safety of our workers is of paramount
importance,” says Claude Schimper, Senior Vice President of
Operations, Russia for Kinross Gold. “By continuing to implement
strict COVID-19 safety measures and testing protocols, including
using the tests supplied by QuestCap and working with QuestCap’s
medical team, we are prioritizing our workers’ health and safety
while maintaining the operation of Kinross’ Russian business.”
The protocols were developed jointly by medical
experts and QuestCap advisors, Dr. Glenn Copeland, Founding CEO of
the Cleveland Clinic Canada, and Dr. Lawrence Steinman, Stanford
University Professor and former Chair of the Standford Program in
Immunology.
About the COVID-19 TestsThe
antibody tests take 8-10 minutes to administer and provide results
within minutes, indicating the presence of antibodies in people
either currently infected by the virus, or in people who may have
been previously ill or exposed, an important step in determining a
safe return to normal life.
The portable RT-PCR analyzers and associated
rapid tests detect the presence of the virus in people who are
currently infected with COVID-19. The analyzers can process 32
Rapid RT-PCR tests in less than one hour. The devices are of
industry leading quality and are currently used by the U.K.
Government to support the country’s testing initiatives.
About QuestCap Inc.QuestCap
Inc. (NEO:QSC; OTC:COPRF; FRA:34C1) seeks out disruptive
technologies, ground-breaking innovations, and exclusive
partnerships to help combat COVID-19 and generate remarkable
risk-adjusted returns for investors. Specifically,
QuestCap offers investors a diversified
investment in the COVID-19 medical space across
three areas; prevention, detection, and
treatment.
QuestCap has a team of renowned global medical
and business advisors that have developed a proprietary business
strategy to capitalize on high-margin opportunities in the
COVID-19 space. This panel includes prominent
immunologist Dr. Lawrence Steinman and Dr. Glenn Copeland, who has
45 years of experience in orthopaedic treatment, foot and ankle
care, and sports medicine.
QuestCap’s primary focus is the sale of COVID-19
IgG/IgM antibody tests authorized by FDA under an EUA for use by
authorized laboratories. This is achieved largely through two
acquisitions: 100% of Collection Sites, LLC and 28% of Colombian
Sanaty IPS. Collection Sites is setting up a series of COVID-19
testing sites across the United States with appointments and
payments handled through the online portal
www.testbeforeyougo.com. Sanaty is setting up a
series of full-service medical clinics offering a complete COVID-19
testing solution.
For additional information, please
contact:
Doug Sommerville,
CEODoug.Sommerville@questcapinc.com
For investing enquires please contact:Evan
Veryard evan.veryard@questcapinc.com
For media enquires please contact:Veronica
Welchveronica@vewprmedia.com+1-508-643-8000
Cautionary Note Regarding
Forward-looking Information
This press release contains "forward-looking
information" within the meaning of applicable Canadian securities
legislation. Forward-looking information includes, but is not
limited to, statements with respect to the sale of COVID-19 test
kits to Kinross Gold; the pursuit by QuestCap of investment
opportunities; and the merits or potential returns of any such
investments. Generally, forward-looking information can be
identified by the use of forward-looking terminology such as
"plans", "expects" or "does not expect", "is expected", "budget",
"scheduled", "estimates", "forecasts", "intends", "anticipates" or
"does not anticipate", or "believes", or variations of such words
and phrases or state that certain actions, events or results "may",
"could", "would", "might" or "will be taken", "occur" or "be
achieved". Forward-looking information is subject to known and
unknown risks, uncertainties and other factors that may cause the
actual results, level of activity, performance or achievements of
the Company, as the case may be, to be materially different from
those expressed or implied by such forward-looking information.
Although the Company has attempted to identify important factors
that could cause actual results to differ materially from those
contained in forward-looking information, there may be other
factors that cause results not to be as anticipated, estimated or
intended. There can be no assurance that such information will
prove to be accurate, as actual results and future events could
differ materially from those anticipated in such statements.
Accordingly, readers should not place undue reliance on
forward-looking information. The Company does not undertake to
update any forward-looking information, except in accordance with
applicable securities laws.
NEITHER THE NEO EXCHANGE NOR ITS REGULATION
SERVICES PROVIDER HAS REVIEWED OR ACCEPTS RESPONSIBILITY FOR THE
ADEQUACY OR ACCURACY OF THIS RELEASE.
Kinross Gold (NYSE:KGC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Kinross Gold (NYSE:KGC)
Historical Stock Chart
From Sep 2023 to Sep 2024